Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands

Citations Over TimeTop 10% of 2013 papers

Abstract

The bromodomain protein module, which binds to acetylated lysine, is emerging as an important epigenetic therapeutic target. We report the structure-guided optimization of 3,5-dimethylisoxazole derivatives to develop potent inhibitors of the BET (bromodomain and extra terminal domain) bromodomain family with good ligand efficiency. X-ray crystal structures of the most potent compounds reveal key interactions required for high affinity at BRD4(1). Cellular studies demonstrate that the phenol and acetate derivatives of the lead compounds showed strong antiproliferative effects on MV4;11 acute myeloid leukemia cells, as shown for other BET bromodomain inhibitors and genetic BRD4 knockdown, whereas the reported compounds showed no general cytotoxicity in other cancer cell lines tested.

Related Papers

• → Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4(2015)1,016 cited
• → Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain(2018)118 cited
• → Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734(2020)85 cited
• → Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk(2016)48 cited
• → Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors(2019)29 cited